Sources checked September 26, 2026.
Read the warning signs
Read the service process and the product description together. A polished presentation cannot answer either on its own.
Begin with the points you can check: the assessor’s name, the dispensing pharmacy, the written product description, and the route for follow-up. Keep each reply with the program terms. Ask for a missing answer before treating an offer as a settled care plan.
Look at the prescription process
Federal law in the September 26, 2026 record required a licensed practitioner’s prescription for dispensing a prescription medicine.
An online pharmacy with no prescription requirement or no pharmacist for questions appears on the Food and Drug Administration (FDA) caution list.
FDA also cautions that the appearance of a website can make an unsafe pharmacy hard to recognize.
Look past the design to the process. Who assesses the request? How can that person ask more? How can you raise your own question? Ask what happens if an assessment does not support the treatment selected on a menu.
| Compare | Ask for a clear answer |
|---|---|
| No clear assessor | Who reviews the history and makes the medical decision? |
| No pharmacy identity | Which pharmacy prepares or dispenses the medicine? |
| No follow-up route | Who answers a medicine question after the order arrives? |
Keep a screenshot or copy of the terms being discussed. If the reply changes the offer, ask for the revised terms as well. Do not rely on a reassuring phrase that cannot be matched to a process.
Check the claim about the product
In the September 26, 2026 record, calling a compounded medicine FDA-approved was a false approval claim.
FDA had recorded cases in which the pharmacy shown on a compounded semaglutide or tirzepatide label either did not exist or had not prepared it.
The pharmacy on the label
Compare the pharmacy name with the public state record. Then ask the pharmacy to clarify a mismatch. Do not assume the program’s name tells you who made the medicine. Use the state board’s record to check the dispensing name.
FDA warned that poor compounding can produce contamination or too much or too little active ingredient, in process information checked September 17, 2026.
Its reports on compounded injectable semaglutide included dosing errors with some hospitalizations, as recorded September 26, 2026.
An active ingredient is the component intended to produce the drug’s effect. Bring any unclear instructions to the actual prescriber or dispensing pharmacist.
A reply about price does not settle a question about the product’s identity. Keep the medicine description, the source check, and the payment terms on separate lines.
Make room for help after the visit
Ask the actual service how to report an unwanted effect and how a medicine question reaches a health professional. Ask which route is for routine questions and which situations belong outside that route. Keep the answer available rather than searching the membership terms during a concern.
Anaphylaxis means an allergic reaction severe enough to threaten life. It can unfold very fast. For severe anaphylaxis symptoms, MedlinePlus says to call the local emergency number or 911. These can include difficulty breathing and swelling involving the tongue or face.
The FDA accepts consumer reports of medicine problems through MedWatch, according to process information checked September 17, 2026.
A report alone cannot establish that a drug caused a problem. It also cannot show how common the problem is among people taking that drug.
Keep the product information and the account of what happened for the treating professional. Reporting and getting care are separate tasks. A guide cannot assess an individual event or replace the person responsible for the care plan.
Notes for this article
- Pharmacy checks
-
FDA checklist for an online pharmacy
FDA links to state pharmacy records
The pharmacy-checking advice was checked September 17, 2026. It covers prescription requirements, access to a pharmacist for questions, and checking a pharmacy’s state license.
- Product concerns
-
FDA concerns about unapproved weight medicines
FDA on compounding problems
The compounded-product reports were checked September 26, 2026.
- Urgent help and reporting
-
MedlinePlus on anaphylaxis
FDA MedWatch reporting
FDA report-data limitations
These process sources were checked September 17, 2026.